Latest Blog Posts Tagged "Research News"
September 30, 2016
Researchers in the Netherlands today announced a study modeled after and complimentary to the MJFF-led Parkinson's Progression Markers Initiative.
September 21, 2016
A new formulation of amantadine to better treat levodopa-induced dyskinesia is entering the home stretch.
September 08, 2016
A new study, funded in part by MJFF, identified a potential common link across different causes of Parkinson's.
September 07, 2016
Austrian biotech AFFiRiS reports a boost dose of its vaccine against key protein alpha-synuclein is safe and elicits antibodies. MJFF funded the trial.
September 01, 2016
In the last few months, Cynapsus Therapeutics Inc. has announced Phase II results of its under-the-tongue strip to alleviate motor symptoms, FDA Fast Track Designation and a buyout.
August 29, 2016
An MJFF-funded study reports promising results around development of a test to detect Parkinson's by measuring the properties of key protein alpha-synuclein.
August 25, 2016
With confidence from MJFF-led studies, Denali Therapeutics today announced it has licensed LRRK2 inhibitor compounds from Genentech.
August 24, 2016
To keep you informed of the Foundation's research investments, we're highlighting a few newly funded grants supporting the development of therapies to address common non-motor symptoms of Parkinson's.
August 23, 2016
A recent editorial from MJFF and J. William Langston, MD, outlines a strategy to develop targeted treatments that could prevent, slow or stop Parkinson's progression.
July 26, 2016
Last month scientists and physicians from around the world gathered at the International Congress of Parkinson's Disease and Movement Disorders to discuss emerging trends in care and research.